2023
NCCN Guidelines® Insights: Survivorship, Version 1.2023.
Sanft T, Day A, Ansbaugh S, Armenian S, Baker K, Ballinger T, Demark-Wahnefried W, Dickinson K, Fairman N, Felciano J, Flores T, Friedman D, Gabel N, Goldman M, Henry N, Hill-Kayser C, Hudson M, Koura D, Lee K, McDonough A, Melisko M, Mooney K, Moore H, Moryl N, Neuman H, O'Connor T, Overholser L, Paskett E, Patel C, Peterson L, Pirl W, Porpiglia A, Rodriguez M, Schapira L, Schwartz A, Smith S, Tevaarwerk A, Yang E, Zee P, McMillian N, Freedman-Cass D. NCCN Guidelines® Insights: Survivorship, Version 1.2023. Journal Of The National Comprehensive Cancer Network 2023, 21: 792-803. PMID: 37549906, DOI: 10.6004/jnccn.2023.0041.Peer-Reviewed Original ResearchConceptsCancer survivorsCognitive functionNCCN guidelinesHealthy behaviorsNCCN Guidelines InsightsAdult-onset cancersSleep disordersRecent guideline updatesVaried needsGuideline updateTreatment recommendationsCare coordinationSurvivorsPhysical problemsDisordersGuidelinesProfessionalsImmunizationCancerSurvivorshipBehaviorRecommendations
2022
NCCN Guidelines® Insights: Survivorship, Version 1.2022.
Sanft T, Day A, Peterson L, Rodriguez MA, Ansbaugh S, Armenian S, Baker KS, Ballinger T, Broderick G, Demark-Wahnefried W, Dickinson K, Fairman NP, Friedman DL, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Khakpour N, Koura D, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, Neuman H, O'Connor T, Overholser L, Paskett ED, Patel C, Pirl W, Porpiglia A, Ruddy KJ, Schapira L, Shockney L, Smith S, Syrjala KL, Tevaarwerk A, Yang EH, Zee P, McMillian NR, Freedman-Cass DA. NCCN Guidelines® Insights: Survivorship, Version 1.2022. Journal Of The National Comprehensive Cancer Network 2022, 20: 1080-1090. PMID: 36240847, DOI: 10.6004/jnccn.2022.0052.Peer-Reviewed Original Research
2019
A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making
Sanft T, Berkowitz A, Schroeder B, Hatzis C, Schnabel C, Brufsky A, Gustavsen G, Pusztai L, Londen G. A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making. Breast Cancer Management 2019, 8: bmt22. DOI: 10.2217/bmt-2019-0001.Peer-Reviewed Original Research